

# Article

Subscriber access provided by Northern Illinois University

# Synthesis and intramolecular azo coupling of 4-diazopyrrole-2carboxylates: selective approach to benzo and hetero [c]-fused 6H-pyrrolo[3,4-c]pyridazine-5-carboxylates

Ekaterina E. Galenko, Alexey V. Galenko, Alexander F. Khlebnikov, Mikhail Sergeevich Novikov, and Julia R. Shakirova

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b01662 • Publication Date (Web): 22 Aug 2016 Downloaded from http://pubs.acs.org on August 23, 2016

# **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Synthesis and intramolecular azo coupling of 4-diazopyrrole-2-carboxylates: selective approach to benzo and hetero [c]-fused 6H-pyrrolo[3,4-c]pyridazine-5-carboxylates Ekaterina E. Galenko, Alexey V. Galenko, Alexander F. Khlebnikov,\* Mikhail S. Novikov,


Julia R. Shakirova

St. Petersburg State University, Institute of Chemistry, 7/9 Universitetskaya nab., St. Petersburg, 199034

Russia

\*Corresponding author e-mail: <u>a.khlebnikov@spbu.ru</u>

## **Abstract Graphic**




# Abstract:

A high yield synthesis of fluorescent benzo, thieno and furo [c]-fused methyl 7-aryl-6*H*-pyrrolo[3,4*c*]pyridazine-5-carboxylates, including unprecedented heterocyclic skeletons, was performed by the transformation of methyl 4-aminopyrrole-2-carboxylate into the corresponding diazo compound, followed by intramolecular azo coupling under acid conditions onto a nucleophilic aryl or hetaryl group in the 3position. Azo coupling is completely regioselective and, according to DFT calculations, kinetically controlled reaction. N-Methylation of 1,3-disubstituted 2*H*-pyrrolo[3,4-*c*]cinnolines occurs selectively at N5 under kinetic control, leading exclusively to 5-methyl-5*H*-pyrrolo[3,4-*c*]cinnoline derivatives.


# INTRODUCTION

Diazoazoles have demonstrated high potential for the synthesis of practically useful polynitrogen compounds.<sup>1</sup> Thus, for example, the preparation of temozolomide, 3-methyl-4-oxoimidazo[5,1d[1,2,3,5]tetrazine-8-carboxamide, which is used as a treatment of some brain cancers,<sup>2</sup> involves reactions of 4-diazo-4*H*-imidazole-5-carboxamide.<sup>3</sup> β-Aminopyrroles, efficient synthesis of which was recently described,<sup>4</sup> are potentially convenient precursors of  $\beta$ -diazopyrroles 1. Analysis of the literature showed that while chemistry of  $\beta$ -diazoindoles is developing widely, for example, 6 articles were published only during 2015,<sup>5</sup> the chemistry of  $\beta$ -diazopyrroles was studied only in one work for the same period.<sup>6</sup> Moreover, only about 20 articles were published<sup>1d, 7</sup> for the time since the release in 1908 of the first work<sup>7a</sup> on  $\beta$ -diazopyrrole chemistry, and this despite the fact that some  $\beta$ -diazopyrroles showed antimicrobial<sup>8</sup> and mutagenic<sup>9</sup> activity. One of the reasons for this may be the relative inaccessibility of the corresponding  $\beta$ -aminopyrroles, which are convenient precursors of  $\beta$ -diazopyrroles. With an effective method for the preparation of alkyl 4-aminopyrrole-2-carboxylates in hand that allows the introduction of a variety of aryl and hetaryl substituents at positions 3 and 5,<sup>4</sup> we decided to synthesize the corresponding diazopyrroles 1 with the aim of studying their intramolecular azo coupling. Such azo coupling could potentially serve as a method for the preparation of 1H-pyrrolo[3,2-c]cinnoline 2, 2H-pyrrolo[3,4*c*]cinnoline **3**, 8*H*-pyrrolo[3,2-*c*]thieno[2,3-*e*]pyridazine **4**, 7*H*-pyrrolo[3,4-*c*]thieno[2,3-*e*]pyridazine **5**, 7H-furo[3,2-c]pyrrolo[3,4-e]pyridazine 6, 8H-furo[3,2-c]pyrrolo[2,3-e]pyridazine 7 and other fused heterocycles (Scheme 1). It is notable that about thirty substituted 1H-pyrrolo[3,2-c]cinnolines (backbone 2) are known,  $^{7e,10}$  while only three compounds with the skeleton 2*H*-pyrrolo[3,4-*c*]cinnoline **3** were reported: (1,3-diphenyl-, 1,3-diphenyl-2-ethyl-2H-pyrrolo[3,4-c]cinnoline (8a, 9) and 1,3-diphenyl-5ethyl-5*H*-pyrrolo[3,4-*c*]cinnoline (10).<sup>7a,b,d</sup> The remaining mentioned heterocyclic systems are until now unknown. Meanwhile fused heteroaromatic molecules containing a pyrrole core have a significant importance in the development of new perspective materials, especially luminophores for bioimaging applications.<sup>11</sup>



1,3-Diphenyl-2*H*-pyrrolo[3,4-*c*]cinnoline **8a** was obtained for the first time by prolonged boiling of diazo compound **11a** in 25% sulfuric acid (Scheme 2).<sup>7a</sup> The formation of the second isomer, 1*H*-pyrrolo[3,2-*c*]cinnoline **12a** as a result of competitive intramolecular azo coupling reaction on the 2-phenyl group was not reported.<sup>7a,d</sup> It has also been shown that compound **8a** occurs as the 2*H*-tautomer, and its alkylation with EtI/EtONa leads to the formation of only 5-ethyl-5*H*-substituted tautomer **10** (Scheme 2).<sup>7d</sup> It is noteworthy that compound **9**, **8a**, and **10** is yellow, red and blue, respectively.<sup>7d</sup> Such a possibility of managing the color of the heterocyclic system by protonation, alkylation, or complexation of a certain skeletal nitrogen atom of the heterocycle is very useful for their application in modern technologies.





ACS Paragon Plus Environment

## **RESULTS AND DISCUSSION**

First we tried to reproduce the intramolecular azo coupling for diazo compound **11a** under conditions<sup>7a</sup> published in 1908 to make sure that the reaction actually proceeds selectively. The synthesis of aminopyrrole **14a** was carried out according to our method from azirine **15a** and the pyridinium salt **16a**.<sup>4</sup> Aminopyrrole **14a** was transformed into diazo compound **11a** by treating with excess of sodium nitrite in acetic acid at about 10 °C for 15 minutes. Diazo compound **11b**, without the 5-phenyl group, was synthesized analogously (Scheme 3).


The structure of 3-diazopyrroles has virtually not been investigated by X-ray analysis, probably because of difficulties in obtaining suitable crystals.<sup>1d</sup> The only, but very inaccurate, structural data was mentioned in a review<sup>1d</sup> for 4-acetyl-3-diazo-2,5-diphenylpyrrole. Moreover, 4-acetyl-5-methyl-2-phenyl-1*H*-pyrrole-3-diazonium nitrate instead of the corresponding diazopyrrole was obtained under diazotization of 3-acetyl-4-amino-2-methyl-5-phenyl-1*H*-pyrrole with NaNO<sub>2</sub>/AcOH.<sup>6</sup> Taking all this into account, crystals of **11a**, suitable for performing a single crystal X-ray analysis, were grown and the X-ray study was performed (see Supporting Information) to be sure of the diazopyrrole structure. The selected X-ray structural data for **11a**, as well as the corresponding data for the mentioned compounds, available from the publications<sup>1d,6</sup> are listed in Table 1. The N<sup>1</sup>-C<sup>2</sup> and C<sup>3</sup>-N<sup>6</sup> bond in diazopyrrole **11a** are much shorter than the corresponding bonds in the 1*H*-pyrrole-3-diazonium nitrate, however the N<sup>6</sup>-N<sup>7</sup> in the diazo compound is much longer. The CNN fragment of diazo compound **11a** has linear geometry. The X-ray bond length and angle are in good accordance with the corresponding data from DFT B3LYP/6-31+g(d,p) calculations.

Refluxing compound **11a** in 25% sulfuric acid for 8 days resulted in the formation of cinnoline **8a** isolated in 72% yield. Analysis of the reaction by TLC and NMR showed the absence of a second possible isomer.

Table 1. Tl	he selected structu	ral data for 3-	diazopyrrole der	ivatives
Bond length, Å; bond angle, grad	$\begin{array}{c} Ph & 7\\ 4 & 1\\ Ph & 5\\ N & 6\\ N & 2\\ 1 & Ph \end{array}$	11a [B3LYP/6- 31+g(d,p)]	$\begin{array}{c} Ac & 7 \\ + & N \\ Ph & 5 \\ N & 6 \\ N & 2 \\ 1 \\ Ph \end{array}$	Ac 7 4 3 N <sup>2</sup> N Me 5 6 HN 2 NO <sub>3</sub> - 2 NO <sub>3</sub> -
<i>l</i> <sub>1-2</sub>	1.315(2)	1.315	-	1.352(3)
<i>l</i> <sub>2-3</sub>	1.442(2)	1.459	-	1.381(3)
<i>l</i> <sub>3-4</sub>	1.437(2)	1.452	-	1.433(3)
<i>l</i> <sub>4-5</sub>	1.385(2)	1.390	-	1.366(3)
<i>l</i> <sub>5-1</sub>	1.400(1)	1.395	-	1.375(3)
<i>l</i> <sub>3-6</sub>	1.324(2)	1.313	1.31(3)	1.353(3)
l <sub>6-7</sub>	1.129(2)	1.136	1.13(3)	1.101(3)
<i>a</i> <sub>3-6-7</sub>	179.3(1)	179.3	171(1)	179.1(3)


Use of 20% aq HBF<sub>4</sub> or glacial acetic acid in place of 25% aq sulfuric acid did not lead to a reduction of the reaction time or to an increase of the reaction yield (55 and 57%, respectively).

# Scheme 3. Synthesis and reactivity of diazopyrroles 11a,b



An attempt to synthesize the 1-unsubstituted analogue **8b** by intramolecular azo coupling of diazo compound **11b** under the same conditions resulted in the formation of a complex mixture of unidentified products and significant resinification of the reaction mixture. To clarify the reasons for the selectivity of cyclization of diazo compound **11a** and the failure in the synthesis of pyrrolocinnoline **8b** the DFT


calculations of cyclization of the corresponding diazonium cations **11'** were performed (Fig. 1). According to the calculation results the barrier for the cyclization of the diazonium cation **11'a**, generated from diazo compound **11a**, on the 4-Ph group, leading eventually to the formation of compound **8a**, is 4.8 kcal/mol lower than the barrier for the cyclization on the 2-Ph group (product **12a**). This difference is large enough to provide complete selectivity of the intramolecular azo coupling. The minimal barrier for the cyclization of diazonium cation **11'b** (from diazo compound **8b**) is 1.7 kcal/mol higher than that of diazonium cation **11'a**. This should result in a relatively lower rate of intramolecular reaction of diazo compound **8b**, but it should not principally change the reactivity. At the same time, unlike compound **8a**, compound **8b** is able to enter into intermolecular azo coupling on the unsubstituted position of the pyrrole ring. For example, the intermolecular reaction of 2,5-diphenylpyrrole-3-diazonium chloride with  $\alpha$ -unsubstituted pyrroles, leading to the corresponding azo compounds, have been implemented by Kreutzberg and Kalter.<sup>7c</sup> Formation of a complex mixture of products and resinification of the reaction mixture in the case of compound **11b** is therefore most likely due to the occurrence of intermolecular azo coupling leading to oligomeric products.



**Fig. 1.** Energy profiles for the intramolecular azo coupling of diazonium cations **11**'. Relative free *Gibbs* energies (in kcal mol<sup>-1</sup>, 298 K, PCM model for H<sub>2</sub>O) computed at the B3LYP/6-31+g(d,p) level.

#### The Journal of Organic Chemistry


From this standpoint, the use of diazo compounds **1**, containing substituents in the 2,3,5-positions, as starting material for intramolecular azo coupling is promising. The presence of a methoxycarbonyl group could potentially preclude the implementation of the intramolecular azo coupling in the harsh reaction conditions mentioned above, due to hydrolysis or decarboxylation of the ester group. To outline the ways of rational choice of diazo compounds **1** for selective intramolecular azo coupling, we performed DFT calculations for the cyclization of diazonium cations **1**' (Fig. 2).




**Fig. 2.** Energy profiles for the intramolecular azo coupling of diazonium cations **1**'. Relative free *Gibbs* energies (in kcal mol<sup>-1</sup>, 298 K, PCM model for H<sub>2</sub>O) computed at the B3LYP/6-31+g(d,p) level.

According to the calculation the barrier for cyclization of diazonium cation 1', generated from diazo compound 1a (R = Ph), on the 3-Ph group, leading to intermediate 17, is 5.1 kcal/mol lower than the barrier for cyclization on the 5-Ph group (intermediate 21). This difference should provide the selective cyclization onto the 3-Ph exclusively. On the other hand, the barrier for the formation of intermediate 17 from 1'a is little higher than that for the cyclization of diazonium cation 11'a into 8'a. From the latter it follows that the diazonium cation 1'a needs even harsher conditions for the cyclization than 11'a. This may make it impossible the intramolecular azo coupling starting from compound 1a, which is potentially

less stable in boiling acid due to the ester group. Since the azo coupling is an electrophilic reaction, an introduction of an electron donating group into the respective benzene ring or replacement of the phenyl group with a more nucleophilic group should lead to a reduction of the cyclization barrier, thus decreasing the reaction time and increasing the probability of obtaining the desired products. According to the calculation, the introduction of a *meta*-methoxy group into the 3-phenyl substituent or replacing the 3-phenyl group with the thiophene-2-yl or fur-2-yl group significantly reduces the cyclization barrier. Similar changes with the 5-phenyl substituent also lead to lowering the respective barriers, which however, are still higher than that for the cyclization on the identical aryl/hetaryl substituent at the 3-position of diazo compound **1**. Then diazo compounds **25a,b** were synthesized (vide infra) and introduced into the azo coupling reaction in order to check reliability of our theoretical predictions for the rational design of pyrrolo[3,4-c]pyridazine systems.





Refluxing of the solution of diazo compound **25a** in 25% aqueous sulfuric acid during 4 d was required for the complete consumption of the starting material. This was accompanied by intensive resinification of the reaction mixture and afforded only trace amounts of cinnoline **26a** (according to <sup>1</sup>H NMR spectroscopy of the reaction mixture). In contrast, cyclization of diazo **25b** proceeded 5 times faster than the cyclization of diazo compound **11a** under the same conditions and cinnoline **26b** was isolated in 80%yield (Scheme 4).

Based on the above theoretical and experimental results, we synthesized a series of diazo pyrroles **25** (Table 2), containing 3-aryl- and hetaryl-substituents which are suitable for intramolecular azo coupling.


## The Journal of Organic Chemistry


Pyrroles **28a-j** were prepared in one-pot mode by the reaction of 5-methoxyisoxazoles **27a-d** with pyridinium ylides **16a-d** under relay catalysis with  $FeCl_2/Et_3N$  leading to 1-(5-methoxycarbonyl-1*H*-pyrrol-3-yl)pyridinium salts, followed by hydrazinolysis, according to published procedure (Table 2).<sup>4</sup> All new compounds were characterized by <sup>1</sup>H and <sup>13</sup>C NMR, IR spectroscopy, and mass-spectrometry.

# Table 2. Synthesis of 4-aminopyrroles 28a-j and 4-diazopyrroles 25a-j

Me0 27	$ \bigvee_{N} + \bigvee_{P} \bigvee_{P} \bigvee_{P} $	1) FeCl <sub>2</sub> 4H <sub>2</sub> O; Et <sub>3</sub> 2) N <sub>2</sub> H <sub>4</sub> ·H <sub>2</sub> O MeCN, 45 °C		R <sup>2</sup> NaNO₂ AcOH, 10 ℃ N	$ \begin{array}{c}                                     $
Entry	$\mathbf{R}^1$	$\mathbf{R}^2$	27+16	28, yield %	25, yield %
1	Ph	Ph	27a+16a	<b>a</b> , 63	<b>a</b> , 89
2	3-MeOC <sub>6</sub> H <sub>4</sub>	Ph	27b+16a	<b>b</b> , 67	<b>b</b> , 76
3	$3-MeOC_6H_4$	$4-BrC_6H_4$	27b+16b	<b>c</b> , 78	<b>c</b> , 98
4	3-MeOC <sub>6</sub> H <sub>4</sub>	4-MeOC <sub>6</sub> H <sub>4</sub>	27b+16c	<b>d</b> , 47	<b>d</b> , 88
5	3-MeOC <sub>6</sub> H <sub>4</sub>	$4-NO_2C_6H_4$	27b+16d	<b>e</b> , 58	<b>e</b> , 99
6	thiophen-2-yl	Ph	27c+16a	<b>f</b> , 47	<b>f</b> , 94
7	thiophen-2-yl	$4-BrC_6H_4$	27c+16b	<b>g</b> , 52	<b>g</b> , 92
8	thiophen-2-yl	4-MeOC <sub>6</sub> H <sub>4</sub>	27c+16c	<b>h</b> , 71	<b>h</b> , 79
9	thiophen-2-yl	$4-NO_2C_6H_4$	27c+16d	<b>i</b> , 15	<b>i</b> , 99
10	benzofuran-2-yl	Ph	27d+16a	<b>j</b> , 44	<b>j</b> , 84


The one-pot procedure for the preparation of 4-aminopyrrolole **28k** having a benzo[*b*]thiophen-2-yl substituent at the C3 atom gave unsatisfactory results, and therefore this compound was synthesized in a stepwise manner (Scheme 5).<sup>4,12</sup>






Aminopyrroles **28** were easily converted into diazopyrroles **25** by the reaction with sodium nitrite in acetic acid (Table 3). The reaction is completed within 15 minutes at a temperature of about 10 °C to give 3-diazopyrroles **25a-j** in high yields. Diazopyrroles are usually bright orange crystals that are stable in the solid state in the absence of light. Compound **25k** with 3-(benzo[*b*]thiophen-2-yl) substituent was not isolated in pure form. According to NMR, the reaction mixture along with the diazotization product contained a significant amount of the intramolecular azo coupling product. Apparently the activation barrier for the azo coupling reaction in this case is sufficiently low and the reaction proceeds already in acetic acid at low temperature.

The cyclization of diazopyrroles **25** to pyrrolo[3,4-*c*]pyridazines **26c-k** was performed by refluxing solutions of the diazopyrroles in 25% sulfuric acid. Typically, the reaction requires 30-36 h, except the synthesis of compound **26k**, which requires only 0.5 h. Compounds **26b-k** were isolated in good yields by a simple workup: the sulphate salt of the product was filtered off, converted to free base by suspending in an aqueous sodium bicarbonate solution, the base obtained was filtered, washed with water and dried (Table 3). Pyrrolo[3,4-*c*]pyridazines **26** are solid, coloured, high-melting compounds.



Compounds 26 may in principle exist in the three tautomeric forms, as shown in the scheme 6.

# Scheme 6. Tautomeric forms of compounds 26b,f,j



According to calculations (Table 4) the tautomer with hydrogen at the pyrrole nitrogen is much more stable than the other two tautomers in solution. The most stable tautomers (**26b-2H**, **26f-7H**, **26j-2H**) have

also a long-wave maximum at ~400 nm in the visible absorption spectra whereas tautomers 26b-4H, 26f-

4H, 26j-4H and 26b-5H, 26f-2H, 26j-5H have a maximum at ~550 and ~ 530 nm, respectively (Table 4).

Table 4. Relative free *Gibbs* energies (298K), the long-wave maximums and the oscillator strengths of tautomers 26b,f,j, (DFT and TD-DFT B3LYP/6-31+g(d,p), PCM model for the corresponding solvents)

	EtOH		l	МеОН		CH <sub>2</sub> Cl <sub>2</sub>		
	rel ∆G, kcal/mol	$\lambda_{\max}, \operatorname{nm}; f$	rel ∆G, kcal/mol	$\lambda_{\max}, \operatorname{nm}; f$	rel ∆G, kcal/mol	$\lambda_{\max}, \operatorname{nm}; f$		
26b-2H	0.0	392; 0.478	0.0	392; 0.468	0.0	393; 0.509		
26b-4H	9.6	569; 0.089	9.5	568; 0.088	9.8	578; 0.090		
26b-5H	5.3	527; 0.254	5.2	525; 0.250	5.4	534; 0.260		
26f-7H	0.0	403; 0.317	0.0	402; 0.309	0.0	402; 0.338		
26f-5H	7.5	563; 0.044	7.5	562; 0.043	7.7	569; 0.044		
26f-4H	4.0	533; 0.165	3.9	527; 0.163	4.6	534; 0.169		
26ј-2Н	0.0	404; 0.356	0.0	404; 0.349	0.0	405; 0.374		
26j-4H	6.2	540; 0.075	6.2	539; 0.074	6.4	546; 0.075		
26j-5H	4.8	524; 0.269	4.8	522; 0.269	4.7	533; 0.281		

UV-VIS spectra in the region 230-700 nm for dichloromethane solutions of compounds **26b,f,j** are shown in Fig. 3. The long-wave absorption band maxima of compounds **26b,f,j** are at 392, 401, 403 nm, respectively (Table 5). This is in accordance with the results of TD-DFT B3LYP/6-31+g(d,p) calculations for the electronic transition from the HOMO to the LUMO of the most stable tautomers **26b-2H**, **26f-7H**, **26j-2H** in dichloromethane (Table 4).




Fig. 3. UV-VIS spectra of compounds 26b, f, j in dichloromethane.

The compounds **26** are luminescent in solution. The photophysical data are given in Table 5 and representative examples of excitation and emission spectra are depicted in Fig. 4. Typically small values of Stokes shifts, together with excited state lifetime in nanosecond domain, clearly indicate that the emission observed originates from the singlet excited state, i.e. fluorescence.




Fig. 4. Room temperature excitation and emission spectra of 26b, f, j in dichloromethane.

ACS Paragon Plus Environment

It was found that the fluorescence properties of **26b,c,d,e** are sensitive to the substituent in the para position of the phenyl group (Fig. 5, Table 5). The Br-substituent does not change the position of the emission maxima but increases the fluorescence quantum yield. The MeO and NO<sub>2</sub> substituents shift emission to redder wavelengths by 29 or 74 nm, respectively, and increase the fluorescence quantum yield more than an order of magnitude.




Fig. 5. Room temperature excitation and emission spectra of 26b,c,d,e in dichloromethane.

Table 5. Photophysical characteristics of 26b,c,d,e,f,j and 26b-5Me in dichloromethane solutions at room temperature,  $\lambda_{ex} = 383-415$  nm (corresponds to the most wavelength maximum of excitation spectrum). Lifetimes ( $\tau$ ) were measured at  $\lambda_{max}$  of the emission bands

Compound	d Absorbance, $\lambda_{max}$ , nm ( $\epsilon$ , 10 <sup>3</sup> ·M <sup>-1</sup> ·cm <sup>-1</sup> )	Emission λ <sub>max</sub> , nm	Excitation λ <sub>max</sub> , nm	τ, ns	QY, %
26b	271 (29), 297 (16), 353 (12),	475	272, 297, 350, 363,	2.23	2.07
	364 (13), 392 (12)		390		
26c	276 (34), 302 (17), 346 (12),	475	274, 298, 349, 364,	0.58	11.37
	365 (14), 395 (14)		393		
26d	277 (27), 302 (15), 356 (11),	504	275, 298, 356, 367,	6.10	28.23
	370 (12), 401 (11)		400		
26e	298 (15), 371 (11), 413 (22),	549	295, 375, 415	2.44	26.19
	436 (18)				

**ACS Paragon Plus Environment** 

26f	272 (17), 293(19), 335 (6),	478	273, 292, 333, 344,	2.13	11.05
	350 (5), 401 (6)		403		
26j	260 (22), 290 (25), 299 (26),	473	291, 297, 336, 348,	3.36	16.72
	331 (8), 347 (6), 403 (5)		408		
26b-5Me	257 (29), 281 (21), 297 (18),	482	268, 291, 341, 359,	2.71	1.86
	335 (10), 345 (13), 371 (5),		383		
	397 (4), 533 (6)				

Fixing other tautomeric forms of the compounds 26, which should have significantly different VIS properties from the most stable, may be realized by alkylation of the nitrogens of the pyridazine fragment of 26. Alkylation of pyrrolocinnoline 8a, existing in 2*H*-tautomeric form, proceeded selectively under the action of EtI/EtONa in EtOH and led to the formation of the 5-ethyl-5*H*-tautomer 10.<sup>7a</sup> To understand the reasons for this selectivity and to evaluate the prospects of the selective alkylation of compounds 26, we performed DFT calculations for the model compounds listed in the Table 6.


Table 6. Relative free *Gibbs* energies (298K) of tautomers 8a, 26b, their Me-derivatives 8a-nMe, 26b-nMe (DFT B3LYP/6-31+g(d,p), PCM for MeOH) and barrier for nucleophilic substitution of Br in MeBr with anion derived from 8a or 26b (DFT B3LYP/6-31+g(d,p){CNH}/LANL2DZ{Br}, 298K, PCM for MeOH)


	Compound	rel ∆G, kcal/mol	Compound	rel ∆G, kcal/mol	rel ∆G <sup>#</sup> , kcal/mol
2 <i>H</i> -tautomer	8a-2H	0.0	8a-2Me	0.0	33.3
4H-tautomer	8a-4H	10.7	8a-4Me	8.1	34.6
5H-tautomer	8a-5H	3.7	8a-5Me	0.3	31.1
2H-tautomer	26b-2H	0.0	26b-2Me	2.2	34.4
4H-tautomer	26b-4H	9.5	26b-4Me	5.2	34.9
5H-tautomer	26b-5H	5.2	26b-5Me	0	30.6

The existence of pyrrolocinnoline **8a** as 2*H*-tautomer corresponds to its greater stability compared with 5*H*- and 4*H*- tautomers (Table 6). Since the relative thermodynamic stabilities of 2-methyl-1,3-diphenyl-2*H*-pyrrolo[3,4-*c*]cinnoline **8a-2Me** and 5-methyl-1,3-diphenyl-5*H*-pyrrolo[3,4-*c*]cinnoline **8a-5Me** are 15

**ACS Paragon Plus Environment** 

almost equal (Table 6), the selective alkylation the cinnoline N5 atom is a kinetically controlled process. The DFT calculations of the thermodynamic parameters for the reaction of MeBr with the anion, formed from pyrrolocinnoline **8a** under deprotonation, showed that the free Gibbs energies of the transition states for N2 and N4 alkylation were by 2.2 and 3.5 kcal/mol greater than for N5 alkylation and ensures the dominant alkylation of the N5 atom of the backbone (Table 6). This result can be explained by steric hindrances for attack of the alkylating agent caused by the Ph-groups in the case of N2 attack and by the 3-Ph-group in the case of N4 attack (Table S8, Supporting Information). In accordance with the calculation results methylation of **8a** by MeI/MeONa in MeOH gave **8a-5Me** as the only product (Scheme 7).





Replacing the 1-Ph group with a CO<sub>2</sub>Me group when passing from compound **8a** to compounds **26** can potentially alter the selectivity of the alkylation. The DFT calculation showed, however, that the free Gibbs energy of the transition states of N2- and N4-methylation of the anion, formed by deprotonation of **26b**, with MeBr are 3.8 and 4.3 kcal/mol greater than that for N5-methylation and that ensures complete selectivity of the reaction. Increasing energy of the transition states under the attack N2 and N4 on MeBr is caused by obstacles for the approach of the alkylating agent, created by the Ph and the MeO<sub>2</sub>C groups in the case of N2, and the 3-Ph-group in the case of N4 (Table S8, Supporting Information). Methylation of

#### The Journal of Organic Chemistry

pyrrolocinnoline **26b** by MeI/MeONa in MeOH in accordance with the theoretical prediction led to the isolation of compound **26b-5Me** as the only product (Scheme 7). The structure of the alkylation product was proven by 2D-NOESY.




Fig. 6. UV-VIS spectra of compounds 26b and 26b-5Me in dichloromethane.

Since the alkylation of compound **26b** occurs at the N5, a substantial change of the electronic structure takes place. This is reflected in the difference between both the structure and the energies of HOMO and LUMO of the compounds **26b** and **26b-5Me**. Fixing the 5*H*-tautomer of compound **26b** via methylation increases the energy of the HOMO and lowers the LUMO energy in the compound **26b-5Me**, the latter changes larger than the former. From a comparison of FMO energies of compounds **26b-5H** and **26b-5Me** (Table S9, Supporting Information) it can be concluded, that this change is not an effect of a methyl group. As a result, the alkylation should lead to a large bathochromic shift of the long-wave band in the absorption spectrum (Table 4), which is observed experimentally (533 nm **26b-5Me** compared to 392 nm **26b**) (Fig. 6).

In conclusion:

Methyl 4-aminopyrrole-2-carboxylates are excellent precursors of methyl 4-diazopyrrole-2-carboxylates. According to DFT calculations cyclization of the diazonium cations derived from 4-diazopyrrole-2-carboxylates in acid should proceed selectively on the nucleophilic 3-aryl/heteroaryl group rather than on the same group in the 5-position of the pyrrole ring. This led to the easy performing high yield synthesis of benzo, thieno and furo [c]-fused 7-aryl-6H-pyrrolo[3,4-c]pyridazine-5-carboxylates, including first representatives of new heterocyclic systems, from the corresponding 4-diazopyrrole-2-carboxylates. The synthesised derivatives of pyrrolo[3,4-c]pyridazine fluoresce in solutions. N-Methylation of 1,3-disubstituted 2H-pyrrolo[3,4-c]cinnolines, which occurs selectively at N5 under kinetic control, leads to a large bathochromic shift of the long-wave band in the VIS absorption spectra.

## **EXPERIMENTAL SECTION**

General Information and Methods. Melting points were determined on a capillary melting point apparatus. <sup>1</sup>H (400 MHz) and <sup>13</sup>C (100 MHz) NMR spectra were determined in CDCl<sub>3</sub> and DMSO-d<sub>6</sub>. Chemical shifts ( $\delta$ ) are reported in parts per million downfield from tetramethylsilane (TMS  $\delta$  = 0.00). <sup>1</sup>H NMR spectra were calibrated according to the residual peak of CDCl<sub>3</sub> (7.26 ppm) or DMSO-d<sub>6</sub> (2.50 ppm). For all new compounds <sup>13</sup>C {<sup>1</sup>H} and <sup>13</sup>C DEPT135 were recorded and calibrated according to the peak of CDCl<sub>3</sub> (77.00 ppm) or DMSO-d<sub>6</sub> (39.51 ppm). Mass spectra were recorded on a HRMS-ESI-QTOF, electrospray ionization, positive mode. IR-spectra were recorded for tablets in KBr, only characteristic absorption is indicated. The photophysical measurements in solution were carried out using CH<sub>2</sub>Cl<sub>2</sub>, which was distilled prior to use. UV/Vis spectra were recorded on a UV-spectrophotometer Emission and excitation spectra in solution were recorded on a spectrofluorimeter. The absolute emission quantum yield in solutions was determined by a comparative method. Fluorescence lifetimes were determined by the TCSPC (Time-Correlated Single Photon Counting) method. The lifetime data were fit

Page 19 of 39

## The Journal of Organic Chemistry

using the Jobin-Yvon software package. Direct quantum yield measurements of the samples were performed at room temperature with an integrating sphere. Single crystal X-ray diffraction experiment was performed on diffractometer at 100K using monochromated  $CuK\alpha$  radiation. Thin-layer chromatography (TLC) was conducted on aluminium sheets with 0.2 mm silica gel with fluorescent indicator. Synthesis of 3-substituted-3-oxopropanoates was performed according to published procedure.<sup>13</sup> Methyl 3-(benzo[b]thiophen-2-yl)-3-oxopropanoate (30). A hexane solution of BuLi (2.5 M, 20.8 mL, 52 mmol) was added to a solution of DIPA (3.85 g, 52 mmol) in absolute THF (10 mL) at -78 °C under an argon atmosphere and the mixture was stirred for 10 min. Methyl acetate (3.85 g, 52 mmol), and then, after an additional 10 min, a solution of methyl benzo[b]thiophen-2-carboxylate (5.00 g, 26 mmol) in absolute THF (20 mL) was added. The reaction mixture was stirred for 30 min and guenched by saturated aqueous NH<sub>4</sub>Cl. The organic layer was separated and the water layer extracted with ether (30 mL). The combined organic solution was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were evaporated and the residue purified by column chromatography on silica gel (light petroleum/EtOAc 6:1). Light yellow oil, 4.21 g (69%, 97% on consumed methyl benzo[b]thiophen-2-carboxylate). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$ = 3.76 (s, 3H), 4.03 (s, 2H), 7.39-7.46 (m, 1H), 7.46-7.50 (m, 1H), 7.85-7.91 (m, 2H), 7.98 (s, 1H). Spectrum demonstrated the presence of about 8 % of the enol form with characteristic signals  $\delta = 5.65$  (s, 1H) и 12.35 (s, 1H) – CH and OH. <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 46.1 (CH<sub>2</sub>), 52.6 (CH<sub>3</sub>), 122.9 (CH), 125.2 (CH), 126.2 (CH), 127.9 (CH), 130.6 (CH), 138.9 (C), 142.5 (C), 142.9 (C), 167.2 (C), 186.2 (C). ESI/HRMS (m/z): 235.0423 calcd for  $C_{12}H_{11}O_3S$  [M + H]<sup>+</sup>, found 235.0419. IR (KBr, cm<sup>-1</sup>): v 3469, 2557, 1744, 1667.

General method for 3-arylisoxazol-5-ones synthesis.<sup>14</sup> A mixture of alkyl 3-aryl-3-oxopropanoate (1.00 mol) and  $H_2NOH \cdot HC1$  (2.50-3.00 mol, 2.50-3.00 eq.) in water (100 mL) was brought to boiling while stirring and boiled for 5 minutes. The mixture was diluted with ethanol (100 mL), and boiled for 40-60 minutes. After cooling, the precipitate was filtered, washed with a mixture EtOH/H<sub>2</sub>O 1:1 and dried.

**3-(3-Methoxyphenyl)isoxazol-5(4***H***)-one (31a)**. Compound **31a** (6.10 g , 87%) was obtained from ethyl 3-(3-methoxylphenyl)-3-oxopropanoate (8.17 g, 36.76 mmol) and H<sub>2</sub>NOH·HCl (7.70 g, 110.00 mmol). Colorless solid, mp 112-113 °C (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.78 (s, 2H), 3.85 (s, 3H), 7.05-7.08 (m, 1H), 7.16-7.18 (m, 1H), 7.25-7.26 (m, 1H), 7.36-7.40 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 34.1 (CH<sub>2</sub>), 55.5 (CH<sub>3</sub>), 111.0 (CH), 118.4 (CH), 119.3 (CH), 128.8 (C), 130.2 (CH), 160.0 (C), 163.0 (C), 174.6 (C). ESI/HRMS (m/z): 214.0480 calcd for C<sub>10</sub>H<sub>9</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup>, found 214.0485. IR (KBr, cm<sup>-1</sup>): v 2924, 1806.

**3-(Benzofuran-2-yl)isoxazol-5(4***H***)-one (31b)**. Compound **31b** (1.64 g, 25%) was obtained from ethyl 3-(3-benzofuran-2-yl)-3-oxopropanoate (7.30 g, 31.4 mmol) and H<sub>2</sub>NOH·HCl (6.95 g, 100.0 mmol). Colorless solid, mp 140-165°C (dec.) (EtOH). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 4.33$  (br s, 0.6H), 5.72 (br s, 0.6H), 7.32-7.36 (m, 1H), 7.43-7.45 (m, 1H), 7.53-7.55 (m, 1H), 7.68-7.70 (m, 1H), 7.75-7.77 (m, 1H), 13.13 (br s, 0.3H); tautomer ratio: 1:2. <sup>13</sup>C NMR spectrum consisted of very wide signals due to the tautomeric equilibrium. ESI/HRMS (m/z): 202.0499 calcd for C<sub>11</sub>H<sub>8</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, found 202.0495. IR (KBr, cm<sup>-1</sup>): v 3108, 1794, 1607.

**3-(Benzo[b]thiophen-2-yl)isoxazol-5(4***H***)-one (31c)**. Compound **31c** (2.33 g, 66%) was obtained from compound **30** (3.90 g, 16.6 mmol) and H<sub>2</sub>NOH·HCl (3.06 g, 44 mmol) in ethanol (without addition of water). Colorless solid, mp > 188 °C (dec) (EtOH). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.41 (br s, 0.95H), 5.79 (br s, 0.44H), 7.45-7.46 (m, 2H), 7.95 (*pseudo-s*, 2H), 8.03-8.05 (m, 1H), 13.35 (br s, 0.32H); tautomer ratio: 1:1. <sup>13</sup>C NMR spectrum consisted of very wide signals due to the tautomeric equilibrium. ESI/HRMS (m/z): 240.0090 calcd for C<sub>11</sub>H<sub>7</sub>NO<sub>2</sub>S [M + Na]<sup>+</sup>, found 240.0096. IR (KBr, cm<sup>-1</sup>): v 1809, 1792.

**General method of 5-methoxyisoxazoles 27.**<sup>14</sup> Isoxazolone (1.00 mmol) was added in small portions to a stirred solution of diazomethane in ether, prepared by reaction of N,N-nitrosomethylcarbamide (2.50-3.00 mmol, 2.50-3.00 eq) with KOH (40% water solution). The reaction mixture was stirred for 30 min and

### The Journal of Organic Chemistry

excess of diazomethane was quenched with acetic acid. The solvent was removed in vacuo and the residue was purified by column chromatography (light petroleum/EtOAc 6:1 - 4:1).

**5-Methoxy-3-(3-methoxyphenyl)isoxazole (27b)**. Compound **27b** (2.95 g, 74%) was obtained from compound **31a** (3.71 g, 19.40 mmol) and *N*,*N*-nitrosomethylcarbamide (6.00 g, 58.00 mmol). Light yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.84 (s, 3H), 4.03 (s, 3H), 5.51 (s, 1H), 6.96-6.99 (m, 1H), 7.26-7.36 (m, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 55.3 (CH<sub>3</sub>), 58.8 (CH<sub>3</sub>), 75.5 (CH), 111.3 (CH), 116.1 (CH), 119.0 (CH), 129.8 (CH), 130.8 (C), 159.8 (C), 164.1 (C), 174.4 (C). ESI/HRMS (m/z): 228.0632 calcd for C<sub>11</sub>H<sub>11</sub>NNaO<sub>3</sub> [M + Na]<sup>+</sup>, found 228.0626. IR (KBr, cm<sup>-1</sup>): v 2950, 1615.

**5-Methoxy-3-(thiophen-2-yl)isoxazole (27c)**. Compound **27c** (2.98 g, 81%), was obtained from 3-(thiophen-2-yl)isoxazol-5(4*H*)-one (3.39 g, 20.29 mmol) and *N*,*N*-nitrosomethylcarbamide (5.44 g, 53.00 mmol). Colorless solid, mp 64-65 °C (hexane-EtOAc). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 4.03 (s, 3H), 5.47 (s, 1H), 7.08-7.10 (m, 1H), 7.39-7.41 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 58.9 (CH<sub>3</sub>), 75.6 (CH), 127.2 (CH), 127.4 (CH), 127.5 (CH), 131.3 (C), 159.4 (C), 174.3 (C). ESI/HRMS (m/z): 182.0271 calcd for C<sub>8</sub>H<sub>8</sub>NO<sub>2</sub>S [M + H]<sup>+</sup>, found 182.0269. IR (KBr, cm<sup>-1</sup>): v 3134, 1612.

**3-(Benzofuran-2-yl)-5-methoxyisoxazole (27d)**. Compound **27d** (535 mg, 99%) was obtained from compound **31b** (503 mg, 2.50 mmol), suspended in THF, and *N*,*N*-nitrosomethylcarbamide (620 mg, 6.00 mmol). Colorless solid, mp 92-95 °C (MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 4.07$  (s, 3H), 5.65 (s, 1H), 7.21-7.22 (m, 1H), 7.26-7.29 (m, 1H), 7.34-7.38 (m, 1H), 7.54-7.56 (m, 1H), 7.62-7.64 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta = 59.0$  (CH<sub>3</sub>), 75.7 (CH), 106.2 (CH), 111.6 (CH), 121.7 (CH), 123.4 (CH), 125.7 (CH), 127.9 (C), 146.1 (C), 155.1 (C), 156.8 (C), 174.5(C). ESI/HRMS (m/z): 216.0657 calcd for C<sub>12</sub>H<sub>10</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, found 216.0660. IR (KBr, cm<sup>-1</sup>): v 3121, 2924, 1737, 1621, 1600.

**3-(Benzo[b]thiophen-2-yl)-5-methoxyisoxazole (27e)**. Compound **27e** (1.21 g, 86%) was obtained from compound **31c** (1.30 g, 6.00 mmol), suspended in THF, and *N*,*N*-nitrosomethylcarbamide (1.61 g, 15.6 mmol). Colorless solid, mp 125-126 °C (MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 4.05 (s, 3H), 5.58 (s, 1H), 7.35-

7.40 (m, 2H), 7.63 (s, 1H), 7.78-7.82 (m, 1H), 7.84-7.87 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 58.9 (CH<sub>3</sub>), 75.8 (CH), 122.5 (CH), 124.1 (CH), 124.1 (CH), 124.7 (CH), 125.6 (CH), 131.5 (C), 139.2 (C), 140.1 (C), 159.7 (C), 174.5 (C). ESI/HRMS (m/z): 232.0427 calcd for C<sub>12</sub>H<sub>10</sub>NO<sub>2</sub>S [M + H]<sup>+</sup>, for 232.0431. IR (KBr, cm<sup>-1</sup>): v 3132, 1614, 1601.

**Methyl 3-(benzo[b]thiophen-2-yl)-2***H***-azirine-2-carboxylate (15c)** was prepared according to the published procedure.<sup>15</sup> A mixture of compound **27e** (880 mg, 3.80 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (152 mg, 0.76 mmol, 20 mol.%) in absolute acetonitrile (25 mL) was stirred for 20h at room temperature under Ar, then filtered and the solvent removed in vacuo. The residue was purified by column chromatography (light petroleum/EtOAc 6:1). Colorless solid, 598 mg (68%), mp 101-102 °C (pentane). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 2.97 (s, 1H), 3.77 (s, 3H), 7.16-7.54 (m, 2H), 7.93 (s, 1H), 7.93-7.95 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 30.8 (CH), 52.4 (CH<sub>3</sub>), 122.9 (CH), 124.3 (C), 125.5 (CH), 125.8 (CH), 127.7 (CH), 133.3 (CH), 138.3 (C), 143.5 (C), 153.3 (C), 171.5 (C). ESI/HRMS (m/z): 232.0427 calcd for C<sub>12</sub>H<sub>10</sub>NO<sub>2</sub>S [M + H]<sup>+</sup>, found 232.0432. IR (KBr, cm<sup>-1</sup>): v 1767, 1721.

**One-pot synthesis of 4-aminopyrroles 28.**<sup>4</sup> A mixture of isoxazole **27** (1.2-1.5 mmol), phenacylpyridinium bromide **16** (1.0 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (0.06–0.08 mmol, 5 mol.% on isoxazole) and NEt<sub>3</sub> (3.0 mmol, 3 eq) in absolute acetonitrile (4 mL) was stirred at 45 °C for 6-7 h. (monitoring by TLC). Hydrazine hydrate (10.0 mmol, 10 eq) was added to the reaction mixture when bromide **16** was consumed. The mixture was stirred at 45 °C for 6-7 h until the completion of the reaction (monitoring by TLC). The solvent was removed in vacuo and the residue was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> or CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1).

Methyl 4-amino-3-(3-methoxyphenyl)-5-phenyl-1*H*-pyrrole-2-carboxylate (28b). Compound 28b (498 mg, 67%) was obtained from compounds 27b (513 mg, 2.50 mmol), 16a (639 mg, 2.30 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (26 mg, 0.13 mmol, 5 mol.%), Et<sub>3</sub>N (700 mg, 6.90 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1150 mg, 23.00 mmol). Light yellow solid, mp 57-58 °C (hexane). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.29 (br s, 2H), 3.72 (s,

3H), 3.84 (s, 3H), 6.89-6.92 (m, 1H), 7.02-7.06 (m, 2H), 7.28-7.31 (m, 1H), 7.34-7.38 (m, 1H), 7.44-7.48 (m, 2H), 7.61-7.63 (m, 2H), 8.87 (br s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta = 51.2$  (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 113.1 (CH), 115.6 (CH), 116.6 (C), 120.7 (C), 121.8 (C), 122.6 (CH), 125.5 (CH), 126.9 (CH), 129.1 (C), 129.16 (CH), 129.22 (CH), 131.7 (C), 134.4 (C), 159.5 (C), 161.5 (C). ESI/HRMS (m/z): 323.1390 calcd for C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 323.1391. IR (KBr, cm<sup>-1</sup>): v 3304, 2952, 1712, 1670, 1604.

Methyl 4-amino-5-(4-bromophenyl)-3-(3-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (28c). Compound 28c (624 mg, 78%) was obtained from compounds 27b (472 mg, 2.30 mmol), 16b (714 mg, 2.00 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (24 mg, 0.12 mmol, 5 mol.%), Et<sub>3</sub>N (400 mg, 6.00 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1150 mg, 23.00 mmol). Colorless solid, mp 177-178 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.62 (s, 3H), 3.72 (s, 2H), 3.77 (s, 3H), 6.89-6.92 (m, 3H), 7.31-7.35 (m, 1H), 7.58 (d, *J* = 8.6 Hz, 2H), 7.74 (d, *J* = 8.6Hz, 2H), 11.44 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 50.7 (CH<sub>3</sub>), 55.0 (CH<sub>3</sub>), 112.4 (CH), 115.7 (CH), 116.7 (C), 118.8 (C), 119.9 (C), 121.2 (C), 122.4 (CH), 128.1 (CH), 128.9 (CH), 130.0 (C), 131.0 (C), 131.2 (CH), 134.8 (C), 158.9 (C), 160.7 (C). ESI/HRMS (m/z): 401.0495 calcd for C<sub>19</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 401.0502. IR (KBr, cm<sup>-1</sup>): v 3314, 1665, 1603.

Methyl 4-amino-3-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (28d). Compound 28d (414 mg, 47%) was obtained from compounds 27b (606 mg, 2.95 mmol), 16c (770 mg, 2.50 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (30 mg, 0.15 mmol, 5 mol.%), Et<sub>3</sub>N (758 mg, 7.50 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1150 mg, 23.00 mmol). Colorless solid, mp 61-64 °C (hexane). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.21 (br s, 2H), 3.71 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 6.88-6.91 (m, 1H), 6.99 (d, *J* = 8.8 Hz, 2H), 7.02-7.06 (m, 2H), 7.33-7.37 (m, 1H), 7.55 (d, *J* = 8.8 Hz, 2H), 8.80 (br s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 51.2 (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 113.0 (CH), 114.7 (CH), 115.6 (CH), 115.9 (C), 121.0 (C), 121.9 (C), 122.6 (CH), 124.3 (C), 127.1 (CH), 128.2 (C), 129.1 (CH), 134.5 (C), 158.7 (C), 159.4 (C), 161.6 (C). ESI/HRMS (m/z): 375.1315 calcd for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>4</sub> [M + Na]<sup>+</sup>, found 375.1311. IR (KBr, cm<sup>-1</sup>): v 3309, 2949, 1709, 1669, 1610. Methyl 4-amino-3-(3-methoxyphenyl)-5-(4-nitrophenyl)-1*H*-pyrrole-2-carboxylate (28e). Compound 28e (322 mg (58%) was obtained from compounds 27b (369 mg, 1.80 mmol), 16d (484 mg, 2.50 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (18 mg, 0.09 mmol, 5 mol.%), Et<sub>3</sub>N (455 mg, 4.50 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (751 mg, 15.00 mmol). Red solid, mp 208 °C. (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.65 (s, 3H), 3.78 (s, 3H), 4.07 (s, 2H), 6.89-6.91 (m, 3H), 7.32-7.38 (m, 1H), 8.05(d, *J* = 8.9 Hz, 2H), 8.23 (d, *J* = 8.9 Hz, 2H), 11.64 (br s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.0 (CH<sub>3</sub>), 55.0 (CH<sub>3</sub>), 112.6 (CH), 115.6 (CH), 118.6 (C), 119.1 (C), 120.9 (C), 122.4 (CH), 123.7 (CH), 125.9 (CH), 129.0 (CH), 132.8 (C), 134.2 (C), 138.5 (C), 144.1 (C), 159.0 (C), 160.6 (C). ESI/HRMS (m/z): 368.1241 calcd for C<sub>19</sub>H<sub>18</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, found 368.1247. IR (KBr, cm<sup>-1</sup>): v 3318, 1671.

Methyl 4-amino-5-phenyl-3-(thiopen-2-yl)-1*H*-pyrrole-2-carboxylate (28f). Compound 28f (135 mg, 47%) was obtained compounds 27c (208 mg, 1.15 mmol), 16a (271 mg, 0.97 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (20 mg, 0.10 mmol, 5 mol.%)), Et<sub>3</sub>N (300 mg, 3.00 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (500 mg, 10.00 mmol). Colorless solid, mp 153-154 °C (Et<sub>2</sub>O-hexane). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.67 (s, 3H), 3.82 (s, 2H), 7.12-7.14 (m, 2H), 7.24-7.27 (m, 1H), 7.40-7.43 (m, 2H), 7.56-7.57 (m, 1H), 7.73-7.75 (m, 2H), 11.50 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 50.8 (CH<sub>3</sub>), 113.2 (C), 116.8 (C), 120.9 (C), 125.9 (CH), 126.2 (CH), 126.3 (CH), 126.9 (CH), 127.4 (CH), 128.4 (CH), 130.3 (C), 131.6 (C), 134.1 (C), 160.4 (C). ESI/HRMS (m/z): 299.0849 calcd for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 299.0857. IR (KBr, cm<sup>-1</sup>): v 3303, 1670, 1604.

Methyl 4-amino-5-(4-bromophenyl)-3-(thiopen-2-yl)-1*H*-pyrrole-2-carboxylate (28g). Compound 28g (429 mg, 52%) was obtained from compounds 27c (453 mg, 2.50 mmol), 16b (785 mg, 2.20 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (25 mg, 0.13 mmol, 5 mol.%), Et<sub>3</sub>N (668 mg, 6.60 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1100 mg, 22.00 mmol). Colorless solid, mp 168 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.67 (s, 3H), 3.88 (s, 2H), 7.10-7.14 (m, 2H), 7.56-7.57 (m, 1H), 7.59 (d, *J* = 8.5 Hz, 2H), 7.72 (d, *J* = 8.5 Hz, 2H), 11.59 (br s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 50.8 (CH<sub>3</sub>), 113.3 (C), 117.3 (C), 119.0 (C), 119.8 (C), 126.0 (CH), 126.9

(CH), 127.5 (CH), 128.2 (CH), 130.7 (C), 130.8 (C), 131.2 (CH), 133.9 (C), 160.4 (C). ESI/HRMS (m/z): 376.9959 calcd for  $C_{16}H_{14}BrN_2O_2S [M + H]^+$ , found 376.9961. IR (KBr, cm<sup>-1</sup>): v 3300, 1679.

Methyl 4-amino-5-(4-methoxyphenyl)-3-(thiopen-2-yl)-1*H*-pyrrole-2-carboxylate (28h). Compound 28h (515 mg, 71%) was obtained from compounds 27c (453 mg, 2.50 mmol), 16c (678 mg, 2.20 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (25 mg, 0.13 mmol, 5 mol.%), Et<sub>3</sub>N (668 mg, 6.60 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1100 mg, 22.00 mmol). Colorless solid, mp 156 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.66 (s, 3H), 3.72 (s, 2H), 3.79 (s, 3H), 6.99 (d, *J* = 8.7 Hz, 2H), 7.11-7.12 (m, 2H), 7.56-7.57 (m, 1H), 7.68 (d, *J* = 8.7 Hz, 2H), 11.43 (br s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 50.7 (CH<sub>3</sub>), 55.1 (CH<sub>3</sub>), 113.5 (C), 113.9 (CH), 115.9 (C), 121.4 (C), 124.1 (C), 125.8 (CH), 126.8 (CH), 127.3 (CH), 127.8 (CH), 129.4 (C), 134.3 (C), 157.9 (C), 160.5 (C). ESI/HRMS (m/z): 329.0960 calcd for C<sub>17</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, found 329.0962. IR (KBr, cm<sup>-1</sup>): v 3290, 1672, 1614.

Methyl 4-amino-5-(4-nitrophenyl)-3-(thiopen-2-yl)-1*H*-pyrrole-2-carboxylate (28i). Compound 28i (115 mg, 15%) was obtained from compounds 27c (453 mg, 2.50 mmol), 16d (710 mg, 2.20 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (25 mg, 0.13 mmol, 5 mol.%), Et<sub>3</sub>N (668 mg, 6.60 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1100 mg, 22.00 mmol). Orange solid, mp 201-202 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.69 (s, 3H), 4.22 (s, 2H), 7.09-7.10 (m, 1H), 7.15-7.16 (m, 1H), 7.60-7.61 (m, 1H), 8.04 (d, *J* = 8.9 Hz, 2H), 8.23 (d, *J* = 8.9 Hz, 2H), 11.79 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.1 (CH<sub>3</sub>), 113.0 (C), 118.5 (C), 119.7 (C), 123.7 (CH), 126.0 (CH), 126.3 (CH), 127.0 (CH), 127.8 (CH), 133.2 (C), 133.5 (C), 138.2 (C), 144.3 (C), 160.3 (C). ESI/HRMS (m/z): 344.0700 calcd for C<sub>16</sub>H<sub>14</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, found 344.0705. IR (KBr, cm<sup>-1</sup>): v 3338, 1679.

Methyl 4-amino-3-(benzofuran-2-yl)-5-phenyl-1*H*-pyrrole-2-carboxylate (28j). Compound 28j (220 mg, 44%) was obtained from compounds 27d (405 mg, 1.88 mmol), 16a (417 mg, 1.50 mmol), FeCl<sub>2</sub>·4H<sub>2</sub>O (20 mg, 0.10 mmol, 5 mol.%), Et<sub>3</sub>N (450 mg, 4.50 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (751 mg, 15.00 mmol). Colorless solid, mp 174-175 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.76 (s, 3H), 4.38 (s, 2H),

7.25-7.30 (m, 4H), 7.43-7.46 (m, 2H), 7.59-7.61 (m, 1H), 7.64-7.7.66 (m, 1H), 7.73-7.75 (m, 2H), 11.73 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.1$  (CH<sub>3</sub>), 105.1 (CH), 108.9 (C), 110.8 (CH), 116.6 (C), 120.6 (CH), 120.7 (C), 122.7 (CH), 123.6 (CH), 126.4 (CH), 126.6 (CH), 128.5 (CH), 128.7 (C), 131.0 (C), 131.3 (C), 150.7 (C), 153.6 (C), 160.2 (C). ESI/HRMS (m/z): 333.1234 calcd for C<sub>20</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 333.1240. IR (KBr, cm<sup>-1</sup>): v 3315, 1666.

Methyl 4-amino-3-(benzo[b]thiophen-2-yl)-5-(4-bromophenyl)-1*H*-pyrrole-2-carboxylate (28k). Hydrazine hydrate (165 mg, 3.3 mmol) was added to a suspension of salt 29 (190 mg, 0.33 mmol) in MeCN/DMSO (20:1, 5 mL) and the reaction mixture was stirred for 10 h at 45-50 °C. The solvents were removed in vacuo, and the residue was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>) to give compound **28k** (80 mg, 56%). Light yellow solid, mp 184-185 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.68 (s, 3H), 4.04 (s, 2H), 7.32-7.40 (m, 3H), 7.60 (d, *J* = 8.6 Hz, 2H), 7.73 (d, *J* = 8.6 Hz, 2H), 7.84-7.87 (m, 1H), 7.94-7.96 (m, 1H), 11.74 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.0 (CH<sub>3</sub>), 113.2 (C), 117.6 (C), 119.2 (C), 120.1 (C), 122.0 (CH), 123.4 (CH), 123.9 (CH), 124.0 (CH), 124.1 (CH), 128.3 (CH), 130.5 (C), 130.5 (C), 131.3 (CH), 134.8 (C), 139.7 (C), 139.8 (C), 160.2 (C). ESI/HRMS (m/z): 427.0110 calcd for C<sub>20</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 427.0108. IR (KBr, cm<sup>-1</sup>): v 3309, 1680.

**1-(4-(Benzo[***b***]thiophen-2-yl)-2-(4-bromophenyl)-5-(methoxycarbonyl)-1***H***-pyrrole-3-yl)pyridine-1ium bromide (29). A mixture of azirine 15c (200 mg, 0.86 mmol), salt 16b (268 mg, 0.75 mmol) and NEt<sub>3</sub> (152 mg, 1.50 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was stirred for 2 days at room temperature. Precipitate was filtered, washed with CH<sub>2</sub>Cl<sub>2</sub>, and dried on air to give compound <b>29** (245 mg, 57%). Light yellow solid, mp 292 °C (dec.) (CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.61 (s, 3H), 7.06 (d, *J* = 8.6 Hz, 2H), 7.15 (s, 1H), 7.23-7.28 (m, 2H), 7.38 (d, *J* = 8.6 Hz, 2H), 7.67-7.68 (m, 1H), 7.76-7.78 (m, 1H), 8.07-8.10 (m, 2H), 8.58-8.62 (m, 1H), 9.01-9.03 (m, 2H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 50.0 (CH<sub>3</sub>), 118.1 (C), 118.5 (C), 121.8 (CH), 123.00 (CH), 123.03 (CH), 123.5 (CH), 124.0 (CH), 125.5 (C), 127.6 (CH), 128.1 (C), 128.2 (CH), 131.2 (CH), 134.0 (C), 134.8 (C), 136.2 (C), 139.5 (C), 139.7 (C), 145.8 (CH), 147.3 (CH), 164.5 (C).

ESI/HRMS (m/z): 489.0267 calcd for  $C_{25}H_{18}BrN_2O_2S$  [M - Br]<sup>+</sup>, found 489.0258. IR (KBr, cm<sup>-1</sup>): v 1693,1618.

**Synthesis of 4-aminopyrroles from 2***H***-azirines and phenacylpyridinium salts.** A mixture of phenacylpyridinium salts **16** (1.00 mmol), azirine (1.20-1.50 mmol, 1.2-1.5 eq) and NEt<sub>3</sub> (3.00 mmol, 3.0 eq). in absolute acetonitrile (8 mL) was stirred at 45-50 °C for 6-8 h until complete consumption of the starting salt (monitoring by TLC). Hydrazine hydrate (10.00 mmol, 10.0 eq) was added to the reaction mixture and stirring continued at 45-50 °C for 6-8 h until the pyridylpyridinium salt (monitoring by TLC) was consumed. The solvent was removed in vacuo and the residue was purified by column chromotography (CH<sub>2</sub>Cl<sub>2</sub>).

**3-Amino-2,4,5-triphenyl-1***H***-pyrrole (14a)**. Compound **14a** (750 mg, 55%) was obtained from azirine **15a** (971 mg, 5.03 mmol), bromide **16a** (1224 mg, 4.40 mmol), Et<sub>3</sub>N (1333 mg, 13.20 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (2200 mg, 44.00 mmol). Light yellow solid, mp 178-180 °C (EtOH-H<sub>2</sub>O) (lit.<sup>7c</sup> data 182-183 °C (benzene)). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.42 (br. s, 2H), 7.15-7.32 (m, 7H), 7.35-7.40 (m, 4H), 7.41-7.46 (m, 2H), 7.57-7.61 (m, 2H), 7.85 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  =115.4 (C), 116.6 (C), 124.5 (CH), 125.3 (CH), 126.5 (CH), 126.6 (CH), 128.2 (C), 128.6 (CH), 128.8 (CH), 129.2 (CH), 130.2 (CH), 132.8 (C), 133.0 (C), 134.4 (C). ESI/HRMS (m/z): 311.1534 calcd for C<sub>22</sub>H<sub>19</sub>N<sub>2</sub> [M + H]<sup>+</sup>, found 311.1531. IR (KBr, cm<sup>-1</sup>): v 3416, 3357, 1598, 1503.

**3-Amino-2,4-diphenyl-1***H***-pyrrole (14b)**. Compound **14b** (355 mg, 70%) was obtained from azirine **15b** (470 mg, 4.00 mmol), bromide **16a** (600 mg, 2.15 mmol), Et<sub>3</sub>N (780 mg, 7.70 mmol) and NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (1500 mg, 30.00 mmol). Light yellow solid, mp 176-177 °C (EtOH-H<sub>2</sub>O) (lit.<sup>16</sup> data 181°C (EtOH)). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 3.41 (br. s, 2H), 6.79 (d, *J* = 3.0 Hz, 1H), 7.19-7.22 (m, 1H), 7.25-7.29 (m, 1H), 7.39-7.45 (m, 4H), 7.49-7.57 (m, 4H), 7.87 (br. s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 115.4 (CH), 116.9 (C), 118.2 (C), 124.7 (CH), 125.3 (CH), 125.9 (CH), 126.6 (C), 127.5 (CH), 128.8 (CH), 129.1 (CH), 133.3 (C),

135.1 (C). ESI/HRMS (m/z): 235.1226 calcd for  $C_{16}H_{15}N_2$  [M + H]<sup>+</sup>, found 235.1230. IR (KBr, cm<sup>-1</sup>): v 3391, 3163, 3046, 1603, 1568.

Synthesis  $\beta$ -diazopyrroles. Aminopyrrole (1.00 mmol) was dissolved (or suspended) in minimal volume of acetic acid, the mixture cooled to 10 °C and saturated aqueous NaNO<sub>2</sub> (2.00-3.00 mmol, 2.0-3.0 eq) was added dropwise. The mixture was stirred for 15-20 min at room temperature, and then diluted with water (20 mL). The precipitate was filtered, washed with water and dried in vacuo. If the product did not crystallize, it was extracted with ether, the organic layer was washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent removed in vacuo.

**3-Diazo-2,4,5-triphenyl-3***H***-pyrrole (11a)**. Compound **11a** (325 mg, 86%) was obtained from compound **14a** (360 mg, 1.20 mmol) and NaNO<sub>2</sub> (166 mg, 2.40 mmol) in 4 mL of AcOH. Orange solid, mp 151-153 °C (EtOH, dec.) (lit.<sup>7c</sup> data 157-158°C (ether, dec.)). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 7.19-7.33 (m, 3H), 7.34-7.50 (m, 6H), 7.51-7.62 (m, 4H), 7.85-7.89 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 122.5 (C), 126.1 (CH), 127.0 (CH), 127.7 (CH), 127.9 (CH), 128.2 (CH), 128.7 (CH), 129.1 (CH), 129.2 (CH), 131.9 (C), 133.4 (C), 135.3 (C), 139.2 (C), 156.0 (C). ESI/HRMS (m/z): 322.1339 calcd for C<sub>22</sub>H<sub>17</sub>N<sub>3</sub> [M + H]<sup>+</sup>, found 322.1341. IR (KBr, cm<sup>-1</sup>): v 2089.

**3-Diazo-2,4-diphenyl-3***H***-pyrrole (11b)**. Compound **11b** (290 mg, 78%) was obtained from compound **14b** (350 mg, 1.50 mmol) and NaNO<sub>2</sub> (210 mg, 3.00 mmol) in 4 mL of AcOH. Brick-red solid, mp 171-172 °C (Et<sub>2</sub>O-hexane) (lit.<sup>17</sup> data 170 (dec) °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.85 (s, 3H), 7.41-7.51 (m, 8H), 7.77-7.80 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 51.8 (CH<sub>3</sub>), 126.7 (CH), 128.6 (CH), 128.9 (CH), 129.1 (CH), 129.2 (CH), 129.8 (CH), 130.3 (C), 131.1 (C), 132.8 (C), 132.8 (C), 136.1 (C), 156.0 (C), 163.1 (C). ESI/HRMS (m/z): 246.1026 calcd for C<sub>16</sub>H<sub>13</sub>N<sub>3</sub> [M + H]<sup>+</sup>, found 246.1015. IR (KBr, cm<sup>-1</sup>): v 2105.

Methyl 3-diazo-2,4-diphenyl-3*H*-pyrrole-5-carboxylate (25a). Compound 25a (427 mg, 89%) was obtained from compound 28a (464 mg, 1.59 mmol) and NaNO<sub>2</sub> (276 mg, 4.00 mmol) in 4 mL of AcOH.

**ACS Paragon Plus Environment** 

Orange solid, mp 134-134 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.85 (s, 3H), 7.41-7.51 (m, 8H), 7.77-7.80 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 51.8 (CH<sub>3</sub>), 126.7 (CH), 128.6 (CH), 128.9 (CH), 129.1 (CH), 129.2 (CH), 129.8 (CH), 130.3 (C), 131.1 (C), 132.8 (C), 132.8 (C), 136.1 (C), 156.0 (C), 163.1 (C). ESI/HRMS (m/z): 326.0900 calcd for C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup>, found 326.0906. IR (KBr, cm<sup>-1</sup>): v 2115, 1712. **Methyl 3-diazo-4-(3-methoxyphenyl)-2-phenyl-3***H***-pyrrole-5-carboxylate (25b). Compound 25b (335 mg, 76%) was obtained from compound 28b (424 mg, 1.32 mmol) and NaNO<sub>2</sub> (228 mg, 3.30 mmol) in 3 mL of AcOH. Orange solid, mp 116-118 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>): \delta = 3.85 (***pseudo***-s, 6H), 6.95-6.98 (m, 1H), 7.05-7.06 (m, 2H), 7.37-7.42 (m, 1H), 7.44-7.50 (m, 3H), 7.77-7.79 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): \delta = 51.8 (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 114.5 (CH), 115.0 (CH), 121.4 (CH), 126.7 (CH), 129.1 (CH), 129.6 (CH), 129.8 (CH), 131.1 (C), 131.5 (C), 132.8 (C), 135.7 (C), 156.0 (C), 159.6 (C), 163.1 (C). ESI/HRMS (m/z): 356.1006 calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>, found 356.1012. IR (KBr, cm<sup>-1</sup>): v 2115, 1708.** 

Methyl 2-(4-bromophenyl)-3-diazo-4-(3-methoxyphenyl)-3*H*-pyrrole-5-carboxylate (25c). Compound 25c (511 mg (98%) was obtained from compound 28c (507 mg, 1.26 mmol) and NaNO<sub>2</sub> (276 mg, 4.40 mmol) in 6 mL of AcOH. Orange solid, mp 88-93 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 3.87 (s, 3H), 3.88 (s, 3H), 6.96-6.99 (m, 1H), 7.03-7.05 (m, 2H), 7.37-7.41 (m, 1H), 7.60-7.69 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  = 51.9 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 114.6 (CH), 115.0 (CH), 121.4 (CH), 124.2 (C), 124.2 (C), 128.1 (CH), 129.7 (CH), 131.3 (C), 131.4 (C), 131.6 (C), 132.3 (CH), 136.0 (C), 154.5 (C), 159.6 (C), 163.0 (C). ESI/HRMS (m/z): 434.0111 calcd for C<sub>19</sub>H<sub>14</sub>BrN<sub>3</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>, found 434.0120. IR (KBr, cm<sup>-1</sup>): v 2157, 1723, 1699.

Methyl 3-diazo-4-(3-methoxyphenyl)-2-(4-methoxyphenyl)-3*H*-pyrrole-5-carboxylate (25d). Compound 25d (345 mg, 88%) was obtained from compound 28d (380 mg, 1.08 mmol) and NaNO<sub>2</sub> (150 mg, 2.20 mmol) in 5 ml of AcOH. Orange solid, dec. > 115 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.74 (m, 3H), 3.81 (m, 3H), 3.87 (m, 3H), 7.06-7.08 (m, 1H), 7.17-7.19 (m, 3H), 7.23 (s, 1H), 7.43-7.7.47

**ACS Paragon Plus Environment** 

(m, 1H), 7.86-7.88 (m, 2H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.9$  (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 55.8 (CH<sub>3</sub>), 106.3 (CH), 111.1 (C), 113.8 (C), 114.1 (CH), 119.7 (CH), 120.9 (C), 121.2 (C), 129.9 (CH), 130.6 (CH), 133.2 (C), 137.7 (C), 160.4 (C), 160.6 (C), 160.8 (C). ESI/HRMS (m/z): 364.1292 calcd. for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, found 364.1292. IR (KBr, cm<sup>-1</sup>): v 2206, 2217, 1734.

Methyl 3-diazo-4-(3-methoxyphenyl)-2-(4-nitrophenyl)-3*H*-pyrrole-5-carboxylate (25e). Compound 25e (110 mg, 99%) was obtained from compound 28e (108 mg, 0.29 mmol) and NaNO<sub>2</sub> (41 mg, 0.60 mmol) in 2 ml of AcOH. Orange solid, mp 93-98 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 3.71$  (s, 3H), 3.80 (s, 3H), 7.02-7.06 (m, 1H), 7.14-7.16 (m, 1H), 7.18-7.20 (m, 1H), 7.41-7.45 (m, 1H), 8.10 (d, J = 8.8 Hz, 2H), 8.38 (d, J = 8.8 Hz, 2H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.2$  (CH<sub>3</sub>), 55.3 (CH<sub>3</sub>), 114.4 (CH), 114.7 (CH), 121.4 (CH), 121.4 (CH), 127.2 (CH), 129.6 (CH), 129.6 (C), 131.3 (C), 131.3 (C), 147.3 (C), 149.6 (C), 149.6 (C), 159.1 (C), 162.6 (C). ESI/HRMS (m/z): 401.0856 calcd. for C<sub>19</sub>H<sub>14</sub>N<sub>4</sub>NaO<sub>5</sub> [M + Na]<sup>+</sup>, found 401.0863. IR (KBr, cm<sup>-1</sup>): v 2159, 1716, 1702.

Methyl 3-diazo-2-phenyl-4-(thiophen-2-yl)-3*H*-pyrrole-5-carboxylate (25f). Compound 25f (219 mg, 94%) was obtained from compound 28f (224 mg, 1.08 mmol) and NaNO<sub>2</sub> (150 mg, 2.20 mmol) in 2 ml AcOH. Orange solid, mp 118-123 °C (dec.) (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 3.90$  (s, 3H), 7.14-7.16 (m, 1H), 7.37-7.38 (m, 1H), 7.43-7.49 (m, 4H), 7.75-7.77 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta = 52.0$  (CH<sub>3</sub>), 126.7 (CH), 127.5 (CH), 127.8 (CH), 128.2 (C), 128.7 (CH), 129.1 (CH), 129.9 (CH), 130.7 (C), 131.4 (C), 132.5 (C), 132.5 (C), 156.2 (C), 163.1(C). ESI/HRMS (m/z): 332.0464 calcd. for C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup>, found 332.0455. IR (KBr, cm<sup>-1</sup>): v 2120, 1712.

Methyl 2-(4-bromophenyl)-3-diazo-4-(thiophen-2-yl)-3*H*-pyrrole-5-carboxylate (25g). Compound 25g (326 mg, 92%) was obtained from compound 28g (343 mg, 0.91 mmol) and NaNO<sub>2</sub> (172 mg, 2.50 mmol) in 5 ml of AcOH. Orange solid, dec. > 114 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.75 (s, 3H), 7.19-7.21 (m, 1H), 7.44-7.45 (m, 1H), 7.72-7.79 (m, 5H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.2 (CH<sub>3</sub>), 122.8 (C), 127.3 (CH) 127.9 (C), 128.2 (CH), 128.5 (CH), 128.5 (C), 128.6 (CH), 130.0 (C), 130.6 (CH),

 131.9 (C), 132.1 (CH), 151.9 (C), 162.7 (C). ESI/HRMS (m/z): 387.9750 calcd. for C<sub>16</sub>H<sub>11</sub>BrN<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 387.9755. IR (KBr, cm<sup>-1</sup>): v 2129, 1713.

Methyl 3-diazo-2-(4-methoxyphenyl)-4-(thiophen-2-yl)-3*H*-pyrrole-5-carboxylate (25h). Compound 25h (335 mg, 79%) was obtained from compound 28h (410 mg, 1.25 mmol) and NaNO<sub>2</sub> (310 mg, 4.50 mmol) in 4 ml of AcOH. Orange solid, mp 104 °C (dec.) (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.78 (s, 3H), 3.85 (s, 3H), 7.13 (d, *J* = 8.8 Hz, 2H), 7.21-7.23 (m, 1H), 7.48-7.49 (m, 1H), 7.79-7.80 (m, 1H), 7.82 (d, *J* = 8.8 Hz, 2H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>) could not be registered due to low solubility and instability of the substance in solution. ESI/HRMS (m/z): 340.0750 calcd. for C<sub>17</sub>H<sub>14</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, found 340.0746. IR (KBr, cm<sup>-1</sup>): v 2188, 2159, 2122, 1732, 1717, 1607.

Methyl 3-diazo-2-(4-nitrophenyl)-4-(thiophen-2-yl)-3*H*-pyrrole-5-carboxylate (25i). Compound 25i (138 mg, 89%) was obtained from compound 28i (151 mg, 0.44 mmol) and NaNO<sub>2</sub> (76 mg, 1.10 mmol) in 2 ml of Ac OH. Orange solid, dec. > 100 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.77 (s, 3H), 7.21-7.23 (m, 1H), 7.47-7.48 (m, 1H), 7.79-7.80 (m, 1H), 8.10 (d, *J* = 8.8 Hz, 2H), 8.37 (d, *J* = 8.8 Hz, 2H). <sup>13</sup>C NMR could not be registered due to low solubility and instability of the substance in solution. ESI/HRMS (m/z): 377.0315 calcd. for C<sub>16</sub>H<sub>10</sub>N<sub>4</sub>NaO<sub>4</sub>S [M + Na]<sup>+</sup>, found 377.0317. IR (KBr, cm<sup>-1</sup>): v 2133, 1712.

**Methyl 4-(benzofuran-2-yl)-3-diazo-2-phenyl-3***H***-pyrrole-5-carboxylate (25j). Compound 25j (160 mg, 84%) was obtained from compound 28j (185 mg, 0.56 mmol) and NaNO<sub>2</sub> (104 mg, 1.50 mmol) in 3 ml of AcOH. Orange solid, dec. > 100 °C (AcOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ = 3.88 (s, 3H), 7.29-7.33 (m, 1H), 7.36-7.40 (m, 1H), 7.48-7.57 (m, 3H), 7.60-7.62 (m, 1H), 7.75-7.77 (m, 1H), 7.86-7.87 (m, 2H), 7.94 (s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): 51.6 (CH<sub>3</sub>), 108.1 (CH), 110.9 (CH), 121.9 (CH), 122.8 (C), 123.6 (CH), 125.6 (CH), 126.6 (CH), 128.2 (C), 129.1 (CH), 129.6 (CH), 129.6 (C), 129.9 (C), 132.5 (C), 147.4 (C), 153.5 (C), 154.0 (C), 163.1(C). ESI/HRMS (m/z): 366.0855 calcd. for C<sub>20</sub>H<sub>13</sub>N<sub>3</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>, found 366.0859. IR (KBr, cm<sup>-1</sup>): v 2134, 1700.** 

Cyclization of 3-diazopyrroles 25 to pyrrolopyridazines 26. The suspension of  $\beta$ -diazopyrrole 25 in 25% H<sub>2</sub>SO<sub>4</sub> was refluxed (107 °C, monitored by TLC) until complete conversion of the starting material. After cooling to room temperature the reaction mixture was filtered and the filter-cake was thoroughly washed with water, suspended in aqueous ethanol and treated with 5% aqueous sodium carbonate solution. The precipitate was filtered off, thoroughly washed with water and dried on air prior to trituration with boiling ether.

**1,3-Diphenyl-2***H***-pyrrolo[3,4-***c***]cinnoline (8a). Compound 8a (104 mg, 72%) was obtained from pyrrole <b>11a** (145 mg, 0.45 mmol). Red crystals, mp 327-330 °C (dec.) (EtOH-H<sub>2</sub>O) (lit.<sup>7f</sup> mp. 330-335°C). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 7.35-7.39 (m, 1H), 7.57-7.67 (m, 7H), 7.80-7.82 (m, 2H), 8.07 (d, J = 7.6 Hz, 1H), 8.43 (d, *J* = 7.6 Hz, 1H), 8.56-8.58 (m, 2H), 13.37 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 104.9 (C), 120.2 (C), 121.2 (CH), 126.7 (CH), 126.7 (C), 126.8 (CH), 126.8 (C), 127.1 (CH), 128.1 (CH), 128.6 (CH), 128.6 (C), 128.7 (CH), 128.7 (C), 129.8 (CH), 129.8 (C), 130.3 (CH), 130.4 (CH), 142.9 (C). ESI/HRMS (m/z): 322.1344 calcd. for C<sub>22</sub>H<sub>16</sub>N<sub>3</sub> [M + H]<sup>+</sup>, found 322.1325. IR (KBr, cm<sup>-1</sup>): v 3048, 1604, 1467.

Methyl 8-methoxy-3-phenyl-2*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26b). Compound 26b (269 mg, 80%) was obtained from compound 25b (335 mg, 1.00 mmol). Yellow-brown crystals, mp 212-213 °C (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 3.98$  (s, 3H), 3.99 (s, 3H), 7.43-7.45 (m, 1H), 7.48-7.52 (s, 1H), 7.57-7.61 (m, 2H), 8.41-8.43 (m, 1H), 8.48-8.49 (m, 2H), 8.91 (s, 1H), 13.74 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.8$  (CH<sub>3</sub>), 55.6 (CH<sub>3</sub>), 106.2 (CH), 111.3 (C), 113.6 (C), 118.9 (CH), 120.3 (C), 128.5 (CH), 128.9 (CH), 129.0 (C), 131.4 (C), 132.0 (CH), 138.3 (C), 140.7 (C), 160.5 (C), 160.7 (C). ESI/HRMS (m/z): 334.1192 calcd. for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 334.1197. IR (KBr, cm<sup>-1</sup>): v 3271, 1703, 1667, 1614.

Methyl 3-(4-bromophenyl)-8-methoxy-2*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26c). Compound 26c (411 mg, 85%) was obtained from compound 25c (483 mg, 1.17 mmol). Brown crystals, mp 222-223 °C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 3.96$  (s, 3H), 3.97 (s, 3H), 7.40-7.43 (m, 1H), 7.76 (d, *J* 

= 8.4 Hz, 2H), 8.37-8.39 (m, 1H), 8.46 (d, J = 8.4 Hz, 2H), 8.83 (s, 1H), 13.71 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.5$  (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 106.2 (CH), 111.7 (C), 113.3 (C), 118.5 (CH), 120.0 (C), 122.1 (C), 128.1 (C), 130.3 (C), 130.4 (CH), 131.2 (CH), 131.9 (C), 132.6 (CH), 138.2 (C), 160.4 (C). ESI/HRMS (m/z): 412.0291 calcd. for C<sub>19</sub>H<sub>15</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 412.0291. IR (KBr, cm<sup>-1</sup>): v 3092, 1710, 1615.

Methyl 8-methoxy-3-(4-methoxyphenyl)-2*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26d). Compound 26d (219 mg, 73%) was obtained from compound 25d (300 mg, 0.83 mmol). Brown crystals, mp 201 °C (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 3.88$  (s, 3H), 4.01 (*pseudo-s*, 6H), 7.15 (d, *J* = 8.9 Hz, 2H), 7.45 (dd, *J* = 9.0, 2.8 Hz, 1H), 8.42 (d, *J* = 9.0 Hz, 1H), 8.49 (d, *J* = 8.9 Hz, 2H), 8.94 (d, *J* = 2.8 Hz, 1H), 13.41 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.4$  (CH<sub>3</sub>), 55.1 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 106.3 (CH), 110.4 (C), 113.4 (C), 113.9 (CH), 118.5 (CH), 120.2 (C), 121.4 (C), 130.1 (CH), 131.6 (C), 131.7 (CH), 138.0 (C), 140.6 (C), 159.9 (C), 160.2 (C), 160.5 (C). ESI/HRMS (m/z): 364.1292 calcd. for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, found 364.1301. IR (KBr, cm<sup>-1</sup>): v 2951, 1699, 1664, 1613.

Methyl 8-methoxy-3-(4-nitrophenyl)-2*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26e). Compound 26e (94 mg (84%) was obtained from compound 25e (300 mg, 0.83 mmol). Dark purple crystals, dec. > 240 °C (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.03 (s, 3H), 4.04 (s, 3H), 7.47-7.50 (m, 1H), 8.40 (d, *J* = 8.9 Hz, 2H), 8.47-8.49 (m, 1H), 8.90 (d, *J* = 8.9 Hz, 2H), 8.99 (s, 1H), 14.04 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.4 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>), 106.1 (CH), 113.4 (C), 114.4 (C), 118.5 (CH), 120.1 (C), 123.2 (CH), 128.3 (C), 128.5 (CH), 131.6 (CH), 136.0 (C), 139.4 (C), 140.4 (C), 146.3 (C), 160.5 (C), 160.9 (C). ESI/HRMS (m/z): 379.1042 calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>, found 379.1049. IR (KBr, cm<sup>-1</sup>): v 1689, 1616, 1597.

Methyl 6-phenyl-7*H*-pyrrolo[3,4-*c*]thieno[2,3-*e*]pyridazine-8-carboxylate (26f). Compound 26f (149 mg, 70%) was obtained from compound 25f (208 mg, 0.67 mmol). Dark green crystals, mp 228-230°C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 4.02$  (s, 3H), 7.50-7.53 (m, 1H), 7.59-7.61 (m, 2H), 8.08-

8.12 (m, 2H), 8.59-8.61 (m, 2H), 14.42 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.5$  (CH<sub>3</sub>), 107.9 (C), 114.9 (C), 124.9 (C), 126.0 (CH), 128.58 (CH), 128.64 (CH), 129.1 (CH), 129.8 (CH), 129.9 (C), 132.0 (C), 138.2 (C), 152.5 (C), 160.3(C). ESI/HRMS (m/z): 310.0650 calcd. for C<sub>16</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 310.0646. IR (KBr, cm<sup>-1</sup>): v 3235, 1673, 1597.

Methyl 6-(4-bromophenyl)-7*H*-pyrrolo[3,4-*c*]thieno[2,3-*e*]pyridazine-8-carboxylate (26g). Compound 26g (264 mg, 89%) was obtained from methyl compound 25g (295 mg, 0.76 mmol). Dark purple crystals, mp 218-221 °C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 4.01$  (s, 3H), 7.79 (d, J = 8.6 Hz, 2H), 8.07 (d, J = 5.5 Hz, 1H), 8.11 (d, J = 5.5 Hz, 1H), 8.57 (d, J = 8.6 Hz, 2H), 14.45 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 51.5$  (CH<sub>3</sub>), 108.5 (C), 114.9 (C), 122.5 (C), 124.7 (CH), 126.2 (C), 128.3 (C), 130.1 (CH), 130.2 (CH), 130.6 (C), 131.6 (CH), 138.1 (C), 152.2 (C), 160.2 (C). ESI/HRMS (m/z): 387.9750 calcd. for C<sub>16</sub>H<sub>11</sub>BrN<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 387.9757. IR (KBr, cm<sup>-1</sup>): v 3086, 1698, 1676.

Methyl 6-(4-methoxyphenyl)-7*H*-pyrrolo[3,4-*c*]thieno[2,3-*e*]pyridazine-8-carboxylate (26h). Compound 26h (178 mg, 61%) was obtained from compound 25h (290 mg, 0.86 mmol). Green crystals, mp 225-227 °C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta = 3.88$  (s, 3H), 4.02 (s, 3H), 7.16 (d, J = 8.5 Hz, 2H), 8.05 (*pseudo*-s, 2H), 8.59 (d, J = 8.5 Hz, 2H), 14.06 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 50.9$  (CH<sub>3</sub>), 55.1 (CH<sub>3</sub>), 114.0 (CH), 114.8 (C), 114.8 (C), 121.6 (C), 124.6 (CH), 125.6 (C), 125.6 (C), 129.3 (CH), 129.8 (CH), 137.8 (C), 137.8 (C), 160.0 (C), 160.1 (C). ESI/HRMS (m/z): 340.0756 calcd. for  $C_{17}H_{14}N_3O_3S [M + H]^+$ , found 340.0765. IR (KBr, cm<sup>-1</sup>): v 3214, 1664,1610.

Methyl 6-(4-nitrophenyl)-7*H*-pyrrolo[3,4-*c*]thieno[2,3-*e*]pyridazine-8-carboxylate (26i). Compound 26i (94 mg, 82%) was obtained from compound 25i (114 mg, 0.33 mmol). Dark purple crystals, dec. > 205 °C (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.04 (s, 3H), 8.10 (d, *J* = 5.5 Hz, 1H), 8.15 (d, *J* = 5.5 Hz, 1H), 8.41 (d, *J* = 8.8 Hz, 2H), 8.93 (d, *J* = 8.8 Hz, 2H), 14.72 (br s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.7 (CH<sub>3</sub>), 110.4 (C), 114.9 (C), 123.8 (CH), 123.8 (CH), 124.9 (C), 126.3 (C), 128.4 (C), 128.7 (CH), 130.4

(CH), 135.4 (C), 138.8 (C), 146.6 (C), 160.2 (C). ESI/HRMS (m/z): 355.0496 calcd. for  $C_{16}H_{11}N_4O_4S$  [M + H]<sup>+</sup>, found 355.0501. IR (KBr, cm<sup>-1</sup>): v 3106, 1699.

Methyl 3-phenyl-2*H*-benzofuro[3,2-*c*]pyrrolo[3,4-*e*]pyridazine-1-carboxylate (26j). Compound 26j (119 mg, 94%) was obtained from compound 25j (126 mg, 0.37 mmol). Brown crystals, mp 256-257 °C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.05 (s, 3H), 7.50-7.54 (m, 1H), 7.60-7.64 (m, 3H), 7.69-7.73 (m, 1H), 7.94-7.96 (m, 1H), 8.41-8.43 (m, 1H), 8.58-8.60 (m, 2H), 14.73 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 51.8 (CH<sub>3</sub>), 106.8 (C), 107.6 (C), 112.5 (CH), 120.2 (CH), 121.8 (C), 124.8 (CH), 128.59 (CH), 128.63 (CH), 128.8 (CH), 128.9 (C), 129.2 (CH), 131.9 (C), 138.0 (C), 142.1 (C), 143.6 (C), 154.7 (C), 160.0 (C). ESI/HRMS (m/z): 366.0849 calcd. for C<sub>20</sub>H<sub>13</sub>N<sub>3</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>, found 366.0855. IR (KBr, cm<sup>-1</sup>): v 3193, 1673.

Methyl 3-(4-bromophenyl)-2*H*-benzo[4,5]thieno[3,2-*c*]pyrrolo[3,4-*e*]pyridazine-1-carboxylate (26k). Compound 26k (30 mg, 79%) was obtained from the mixture of compound 25k and 26k mixture (38 mg, 0.09 mmol). Brown crystals, mp 266-268 °C (dec.) (EtOH-H<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.07 (s, 3H), 7.69-7.74 (m, 2H), 7.80 (d, *J* = 8.6 Hz, 2H), 8.19-8.22 (m, 1H), 8.63 (d, *J* = 8.6 Hz, 2H), 8.72-8.73 (m, 1H), 14.46 (br. s, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 53.3 (CH<sub>3</sub>), 121.9 (CH), 123.2 (C), 123.9 (CH), 124.3 (C), 125.9 (C), 126.7 (C), 126.9 (C), 130.26 (CH), 130.29 (C), 131.4 (CH), 131.7 (CH), 132.1 (CH), 132.8 (C), 140.4 (C), 154.2 (C), 154.5 (C), 167.6 (C). ESI/HRMS (m/z): 437.9920 calcd. for C<sub>20</sub>H<sub>13</sub>BrN<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, found 437.9906. IR (KBr, cm<sup>-1</sup>): 3222, 1679.

**Methylation of pyrrolocinnolines.** Cinnoline **26** was dissolved in a solution of NaOMe in methanol, prepared from Na (2.00-4.00 eq) and absolute MeOH (5 mL), and then methyl iodide (3.00-10.00 equiv) was added. The reaction mixture was stirred for 12 hours at room temperature. All the volatiles were removed in vacuo and the residue was treated with aqueous ammonium chloride. The precipitate formed was filtered off, washed with water and dried prior to column chromatography on silica (light

petroleum/EtOAc 6:1 - 0:1). The substance obtained was treated with boiling ether, filtered and dried on air.

**5-Methyl-1,3-diphenyl-5***H***-pyrrolo[3,4-***c***]cinnoline (8a-5Me). Compound 8a-5Me (73 mg, 57%) was obtained from cinnoline 8a (124 mg, 0.39 mmol) sodium (31 mg, 1.35 mmol) and methyl iodide (570 mg, 4.00 mmol). Dark blue crystals, mp 225-227 °C (hexane-EtOAc). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): \delta = 4.54 (s, 3H), 7.37 (t,** *J* **= 7.3 Hz, 1H), 7.42 (t,** *J* **= 7.3 Hz, 1H), 7.48-7.61 (m, 5H), 7.64-7.67 (m, 1H), 7.87 (d,** *J* **= 7.2 Hz, 2H), 8.05-8.07 (m, 1H), 8.32-8.34 (m, 1H), 8.49 (d,** *J* **= 7.2 Hz, 2H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>): \delta = 46.5 (CH<sub>3</sub>), 104.0 (CH), 117.5 (CH), 121.5 (CH), 122.4 (CH), 127.0 (CH), 127.3 (CH), 127.6 (CH), 127.8 (CH), 128.3 (CH), 128.5 (CH), 128.6 (CH), 128.6 (CH), 132.2 (C), 134.7 (C), 137.1 (C), 137.8 (C), 143.6 (C), 145.2 (C). ESI/HRMS (m/z): 336.1495 calcd for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub> [M + H]<sup>+</sup>, found 336.1505. IR (KBr, cm<sup>-1</sup>): v 3446, 1679, 1602.** 

Methyl 8-methoxy-5-methyl-3-phenyl-5*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26b-5Me). Compound 26b-5Me (87 mg, 64%) was obtained from compound 26b (131 mg, 0.39 mmol), sodium (36 mg, 1.57 mmol) and methyl iodide (560 mg, 3.95 mmol). Dark violet crystals, mp 227-229 °C (hexane-EtOAc). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 4.08 (s, 3H), 4.10 (s, 3H), 4.56 (s, 3H), 7.30-7.33 (m, 1H), 7.35-7.39 (m, 1H), 7.46-7.50 (m, 2H), 7.74-7.76 (m, 1H), 8.51-8.53 (m, 2H), 9.57-9.58 (m, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  = 48.2 (CH<sub>3</sub>), 51.3 (CH<sub>3</sub>), 55.8 (CH<sub>3</sub>), 107.2 (CH), 115.4 (C), 120.1 (CH), 120.3 (CH), 123.9 (C), 127.0 (CH), 127.8 (C), 128.5 (CH), 128.9 (C), 134.6 (C), 140.9 (C), 142.9 (C), 159.5 (C), 165.4 (C). ESI/HRMS (m/z): 348.1343 calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 348.1351. IR (KBr, cm<sup>-1</sup>): v 2944, 1683, 1618.

Methyl 3-(4-bromophenyl)-8-methoxy-5-methyl-5*H*-pyrrolo[3,4-*c*]cinnoline-1-carboxylate (26c-5Me). Compound 26c-5Me (57 mg, 55%) was obtained from compound 26c (100 mg, 0.24 mmol), sodium (51 mg, 2.22 mmol) and methyl iodide (340 mg, 2.40 mmol). Dark violet crystals, mp 227-229 °C (hexane-EtOAc). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  = 3.96 (s, 3H), 4.06 (s, 3H), 4.74 (s, 3H), 7.54(dd, *J* = 9.5, 2.9

Hz, 1H), 7.68 (d, J = 8.6 Hz, 2H), 8.30 (d, J = 9.5 Hz, 1H), 8.44 (d, J = 8.6 Hz, 2H), 9.44 (d, J = 2.9 Hz, 1H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta = 47.6$  (CH<sub>3</sub>), 50.7 (CH<sub>3</sub>), 55.5 (CH<sub>3</sub>), 107.3 (CH), 114.9 (C), 119.6 (CH), 119.8 (CH), 120.5 (C), 123.6 (C), 124.7 (C), 128.5 (CH), 128.7 (C), 131.0 (CH), 133.6 (C), 140.6 (C), 141.4 (C), 159.3 (C), 165.0 (C). ESI/HRMS (m/z): 426.0448 calcd for C<sub>20</sub>H<sub>17</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, found 426.0455. IR (KBr, cm<sup>-1</sup>): v 3436, 2091, 1668, 1618.

# ASSOCIATED CONTENT

# **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc...

NMR spectra for all new compounds, crystallographic data for compound **11a**, computation details: energies of the reactants, transition states, their Cartesian coordinates. (PDF). Crystallographic data for **11a** (CIF)

# ACKNOWLEDGMENTS

We gratefully acknowledge the financial support of the Russian Science Foundation (Grant No. 16-13-10036). This research was carried out using resources of the X-ray Diffraction Centre, the Centre for Magnetic Resonance, the Computer Centre, the Centre for Optical and Laser Materials Research and the Centre for Chemical Analysis and Materials of St. Petersburg State University.

# REFERENCES

 (a) Mokrushin, V. S.; Sadchikova, E. V. Chemistry of heterocyclic diazo compounds, St. Petersburg, Russia: Prospekt Nauki, 2013, 224 p.; (b) da Silva, F. C.; Jordão, A. K.; da Rocha, D. R.; Ferreira, S. B.; Cunha, A. C.; Ferreira, V. F. *Curr. Org. Chem.* 2012, 16, 224-251; (c) Zollinger, H. Diazo Chemistry. I. Aromatic and heteroaromatic compounds, VCH: Weinheim, Germany, 1994, 454 p.; (d) Cirrincione, G.; Almerico, A. M.; Aiello, E.; Dattolo, G., *Adv. Heterocycl. Chem.* 1990, *48*, 65-175 (and references cited therein); (e) Elnagdi, M.H.; Zayed, E.M.; Abdou, S. *Heterocycles* 1982, *19*, 559-

**ACS Paragon Plus Environment** 

578; (f) Tišler, M.; Stanovik, B. Chem. Heterocycle. Compd. 1980, 443-463; (g) Butler, R.N. Chem. Rev. 1975, 75, 241–257.

- (a) Tatar, Z.; Thivat, E.; Planchat, E.; Gimbergues, P.; Gadea, E.; Abrial, C.; Durando, X. *Cancer. Treat. Rev.* 2013, *39*, 125-135; (b) Hansen, N.; Wittig, A.; Hense, J.; Kastrup, O.; Gizewski, E. R.; Van de Nes, J. A. P. *Eur. J. Med. Res.* 2011,*16*, 415-419; (c) Kizilarslanoglu, M. C.; Aksoy, S.; Yildirim, N. O.; Ararat, E.; Sahin, I.; Altundag, K. *J. BION* 2011, 16, 547-550.
- (a) Stevens, M. F. G.; Hickman, J. A.; Stone, R.; Gibson, N. W.; Baig, G. U.; Lunt, E.; Newton, C. G. *J. Med. Chem.*, **1984**, , 196–201; (b) Wheelhouse, R. T.; Wilman, D. E. V.; Thomson, W.; Stevens, M. F. G. *J. Chem. Soc., Perkin Trans. 1* **1995**, 249–252.
- Galenko, E. E.; Tomashenko, O. A.; Khlebnikov, A. F., Novikov, M. S. Org. Biomol. Chem. 2015, 13, 9825-9833.
- (a) Wang, C.; Zhang, H.; Lang, B.; Ren, A.; Lu, P.; Wang, Y. Org. Lett. 2015, 17, 4412-4415; (b)
   Wu, M.-Y.; He, W.-W.; Liu, X.-Y.; Tan, B. Angew. Chem. Int. Ed. 2015, 54, 9409-9413; (c) Sheng,
   G.; Huang, K.; Ma, S.; Qian, J.; Lu, P.; Wang, Y. Chem. Commun. 2015, 51, 11056-11059; (d) Jing,
   C.; Xing, D.; Wang, C.; Hu, W. Tetrahedron 2015, 71, 3597-3602; (e) Coffey, K. E.; Moreira, R.;
   Abbas, F. Z.; Murphy, G. K. Org. Biomol. Chem. 2015, 13, 682-685; (f) Karthik, G.; Rajakaran, T.;
   Sridhar, B.; Reddy, B. V. S. Tetrahedron Lett. 2015, 55, 7064-7067.
- Parrino, B.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Màtyus, P.; Cirrincione, G.; Diana,
   P. *Tetrahedron.* 2014, *70*, 7318-7321.

**ACS Paragon Plus Environment** 

G.; Almerico, A. M.; Aiello, E. J. Heterocycl. Chem. 1989, 26, 1747-1749; (g) Ceraulo, L.; Agozzino,
P.; Ferrugia, M.; Plescia, S.; Sprio, V. J. Heterocycl. Chem. 1990, 27, 135-138; (h) Buscemi, S.; Pace,
A.; Cirrincione, G.; Diana, P. Heterocycles 1999, 51, 1631-1638.

- Cirrincione, G.; Almerico, A. M.; Dattolo, G.; Aiello, E.; Grimaudo, S.; Diana, P.; Misuraca, F. Farmaco 1992, 47, 1555-1562.
- 9. Cirrincione, G.; Almerico, A. M.; Grimaudo, S.; Diana, P.; Mingoia, F.; Barraja, P.; Misuraca, F. *Farmaco* **1996**, 51, 49-52.
- (a) Cirrincione, G.; Dattolo, G.; Almerico, A.;M.; Aiello, E. *Heterocycles* 1985, *23*, 2635-2638; (b)
   Dattolo, G.; Cirrincione, G.; Almerico A. M.; Lamartina, L.; Aiello, E. A. *J. Chem. Res. Synop.* 1985, 164-165; (c) Ames, D. E.; Bull, D. *Tetrahedron* 1982, *38*, 383-387.
- For recent examples see: (a) Yu, C.; Wu, Q.; Wang, J.; Wei, Y.; Hao, E.; Jiao, J. Org. Chem. 2016, 81, 3761-3770; (b) Sareen, D.; Lee, J. H.; Hwang, H.; Yoo, S.; Lee, C.-H. Chem. Commun. 2016, 52, 5852-5855; (c) Kim, L. E.; Lee, Y.; Lee, S.; Park, S. B. Acc. Chem. Res. 2015, 48, 538–547; (d) Tomashenko, O. A.; Khlebnikov, A. F.; Mosiagin, I. P.; Novikov, M. S.; Grachova, E. V.; Shakirova, J. R.; Tunik, S. P. RSC Adv., 2015, 5, 94551-94561; (e) Yang, D.-T.; Radtke, J.; Mellerup, S. K.; Yuan, K.; Wang, X.; Wagner, M.; Wang, S. Org. Lett., 2015, 17, 2486-2489; (f) Liu, G.; Chen, D.; Kong, L.; Shi, J.; Tong, B.; Zhi, J.; Feng, X.; Dong, Y. Chem. Commun., 2015, 51, 8555-8558.
- 12. Khlebnikov, A. F.; Golovkina, M. V.; Novikov, M. S.; Yufit, D. S. Org. Lett. 2012, 14, 3768-3771.
- 13. Clark, A. D.; Ha, U. T.; Prager, R. H.; Smith, J. A. Aust. J. Chem. 1999, 52, 1029-1033.
- 14. Clark, A. D.; Janowski, W. K.; Prager, R. H. Tetrahedron, 1999, 55, 3637-3647.
- 15. Auricchio, S.; Bini, A.; Pastormelo, E.; Truscello, A. M. Tetrahedron, 1997, 53, 10911-10920.
- 16. Nomine, G.; Penassel, L.; Dalaroff, V. Annales Pharm. Franc. 1958, 16, 436-441.
- Moore, R. G. D.; Woitach, P. T. Light-sensitive layers for photomechanical reproduction. GB Pat. 816382, 1959.

**ACS Paragon Plus Environment**